Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study.
Read Original Article: Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer »
